MOLECULIN BIOTECH, INC. (NASDAQ:MBRX) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
MOLECULIN BIOTECH, INC. (NASDAQ:MBRX) Files An 8-K Regulation FD Disclosure
On November 19, 2019, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing it now has preliminary data from its clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma (“CTCL”), which was published in Blood in conjunction with the American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019.
The information contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (“Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description
99.1 Press Release dated November 19, 2019
Moleculin Biotech, Inc. Exhibit
EX-99.1 2 exh991-pressreleasectcldata.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma; supports phase 2 studyHOUSTON,…
To view the full exhibit click
EX-99.1 2 exh991-pressreleasectcldata.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Moleculin Announces Positive Trial Data with 100% Safe Delivery of p-STAT3 Inhibitor and Efficacy in Majority of Patients Preliminary results from phase 1 clinical trial of WP1220 for treatment of cutaneous T-cell lymphoma; supports phase 2 studyHOUSTON,…
To view the full exhibit click
hereAbout MOLECULIN BIOTECH, INC. (NASDAQ:MBRX)
Moleculin Biotech, Inc. is a preclinical and clinical-stage pharmaceutical company. The Company is focused on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, which it refers to as Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). Annamycin is a Phase II clinical-stage anthracycline and liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms. It has over two other drug development projects in progress, one involving a portfolio of small molecules, which it refers to as the WP1066 Portfolio, focused on the modulation of key oncogenic transcription factors involved in the progression of cancer, and the WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer in general, and glioblastoma. As of September 30, 2016, it had not generated any revenue from its operations.
